sFIDA Technology

surface-based fluorescence distribution analysis

sFIDA is a platform technology for quantitation and sizing of single protein aggregates.

sFIDA combines the selectivity of an immunological assay with the sensitivity of high-resolution fluorescence microscopy. It features single particle sensitivity, absolute specificity for aggregates and a 4 log dynamic range of size and concentration.

The technology can be applied to oligomer based diagnostics of Alzheimer’s and Parkinson’s disease as well as counting of single viral particles. Furthermore, sFIDA is perfectly suited for development and QC of biologicals.

sFIDA Technology

sFIDA Technology

sFIDA (surface-based fluorescence intensity distribution analysis) is a platform technology for quantitating and sizing single protein aggregates.

sFIDA combines the selectivity of an immunological assay with the sensitivity of fluorescence microscopy. sFIDA features single particle sensitivity and absolute specificity for aggregates.

sFIDA Technology

surface-based fluorescence intensity distribution analysis

Peer-reviewed Publications

1 Wang-Dietrich, L. et al. The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer’s disease. J Alzheimers Dis 34, 985-994, doi:10.3233/JAD-122047 (2013).

2 Hulsemann, M. et al. Biofunctionalized Silica Nanoparticles: Standards in Amyloid-beta Oligomer-Based Diagnosis of Alzheimer’s Disease. J Alzheimers Dis 54, 79-88, doi:10.3233/JAD-160253 (2016).

3 Kuhbach, K. et al. Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay. Front Neurosci 10, 8, doi:10.3389/fnins.2016.00008 (2016).

4 Herrmann, Y. et al. Nanoparticle standards for immuno-based quantitation of alpha-synuclein oligomers in diagnostics of Parkinson’s disease and other synucleinopathies. Clin Chim Acta 466, 152-159, doi:10.1016/j.cca.2017.01.010 (2017).

5 Herrmann, Y. et al. sFIDA automation yields sub-femtomolar limit of detection for Abeta aggregates in body fluids. Clin Biochem 50, 244-247, doi:10.1016/j.clinbiochem.2016.11.001 (2017).

6 Kravchenko, K. et al. Analysis of anticoagulants for blood-based quantitation of amyloid beta oligomers in the sFIDA assay. Biol Chem 398, 465-475, doi:10.1515/hsz-2016-0153 (2017).

7 Kulawik, A. et al. Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases. FEBS Lett 592, 516-534, doi:10.1002/1873-3468.12983 (2018).

8 Schemmert S., et al., Abeta Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology. Mol Neurobiol 56(3):2211-2223, doi: 10.1007/s12035-018-1209-3 (2019).

9 Kass, B., et al., Aβ oligomer concentration in mouse and human brain and its drug induced reduction ex vivo. Cell Reports Medicine, 3, 100630 https://doi.org/10.1016/j.xcrm.2022.100630 (2022).

10 Blömeke, L. et al., Quantitative detection of α-synuclein and tau oligomers and other aggregates by digital single particle counting.  NPJ Parkinsons Dis., 8, 68. https://doi.org/10.1038/s41531-022-00330-x (2022).

11 Schaffrath, A. et al., Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool,  NPJ Parkinsons Dis., 9, 14. https://doi.org/10.1038/s41531-023-00458-4 (2023).

12 Pils, M et al., Development and Implementation of an Internal Quality Control Sample to Standardize Oligomer-Based Diagnostics of Alzheimer’s Disease. Diagnostics 2023, 13, 1702. https://doi.org/10.3390/diagnostics13101702 (2023)